Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 155

1.

Is Conversion from Mycophenolate Mofetil to Enteric-Coated Mycophenolate Sodium Justifiable for Gastrointestinal Quality of Life?

Gardiner KM, Tett SE, Staatz CE.

Drugs R D. 2018 Dec;18(4):271-282. doi: 10.1007/s40268-018-0254-8. Review.

PMID:
30426342
2.

Psychiatric adverse events in oseltamivir prophylaxis trials: Novel comparative analysis using data obtained from clinical study reports.

Jones M, Tett SE, Del Mar C.

Pharmacoepidemiol Drug Saf. 2018 Nov;27(11):1217-1222. doi: 10.1002/pds.4651. Epub 2018 Sep 12.

PMID:
30209862
3.

Evaluation of Multiple Linear Regression-Based Limited Sampling Strategies for Enteric-Coated Mycophenolate Sodium in Adult Kidney Transplant Recipients.

Brooks EK, Tett SE, Isbel NM, McWhinney B, Staatz CE.

Ther Drug Monit. 2018 Apr;40(2):195-201. doi: 10.1097/FTD.0000000000000486.

PMID:
29461443
4.

Importance of the Pre-Industrial Baseline in Determining the Likelihood of Exceeding the Paris Limits.

Schurer AP, Mann ME, Hawkins E, Tett SFB, Hegerl GC.

Nat Clim Chang. 2017 Aug;7(8):563-567. doi: 10.1038/nclimate3345. Epub 2017 Jul 24.

5.

Development of Improved Dosing Regimens for Mycophenolate Mofetil Based on Population Pharmacokinetic Analyses in Adults with Lupus Nephritis.

Abd Rahman AN, Tett SE, Abdul Gafor HA, McWhinney BC, Staatz CE.

Eur J Drug Metab Pharmacokinet. 2017 Dec;42(6):993-1004. doi: 10.1007/s13318-017-0420-3.

PMID:
28536776
6.

New-Onset Diabetes After Statin Exposure in Elderly Women: The Australian Longitudinal Study on Women's Health.

Jones M, Tett S, Peeters GM, Mishra GD, Dobson A.

Drugs Aging. 2017 Mar;34(3):203-209. doi: 10.1007/s40266-017-0435-0.

PMID:
28138911
7.

Ezetimibe: Use, costs, and adverse events in Australia.

Hollingworth SA, Ostino R, David MC, Martin JH, Tett SE.

Cardiovasc Ther. 2017 Feb;35(1):40-46. doi: 10.1111/1755-5922.12236.

PMID:
27860332
8.

Population Pharmacokinetic Modelling and Bayesian Estimation of Tacrolimus Exposure: Is this Clinically Useful for Dosage Prediction Yet?

Brooks E, Tett SE, Isbel NM, Staatz CE.

Clin Pharmacokinet. 2016 Nov;55(11):1295-1335. Review.

PMID:
27138787
9.

Associations of Guideline Recommended Medications for Acute Coronary Syndromes With Fall-Related Hospitalizations and Cardiovascular Events in Older Women With Ischemic Heart Disease.

Peeters G, Tett SE, Hollingworth SA, Gnjidic D, Hilmer SN, Dobson AJ, Hubbard RE.

J Gerontol A Biol Sci Med Sci. 2017 Feb;72(2):259-265. doi: 10.1093/gerona/glw111. Epub 2016 Jul 6.

PMID:
27384327
10.

Associations Between Statin Use and Physical Function in Older Adults from The Netherlands and Australia: Longitudinal Aging Study Amsterdam and Australian Longitudinal Study on Women's Health.

van Boheemen L, Tett SE, Sohl E, Hugtenburg JG, van Schoor NM, Peeters GM.

Drugs Aging. 2016 Jun;33(6):437-45. doi: 10.1007/s40266-016-0370-5.

PMID:
27138957
11.
12.

Actions following adverse drug events - how do these influence uptake and utilisation of newer and/or similar medications?

Barozzi N, Peeters GM, Tett SE.

BMC Health Serv Res. 2015 Nov 6;15:498. doi: 10.1186/s12913-015-1165-9.

13.

The effect of dose and type of proton pump inhibitor use on risk of fractures and osteoporosis treatment in older Australian women: A prospective cohort study.

van der Hoorn MMC, Tett SE, de Vries OJ, Dobson AJ, Peeters GMEEG.

Bone. 2015 Dec;81:675-682. doi: 10.1016/j.bone.2015.08.024. Epub 2015 Aug 28.

PMID:
26319499
14.

Clinical Pharmacokinetics of Once-Daily Tacrolimus in Solid-Organ Transplant Patients.

Staatz CE, Tett SE.

Clin Pharmacokinet. 2015 Oct;54(10):993-1025. doi: 10.1007/s40262-015-0282-2. Review.

PMID:
26038096
15.

Exposure-effect relationship of mycophenolic acid and prednisolone in adult patients with lupus nephritis.

Abd Rahman AN, Tett SE, Abdul Gafor HA, McWhinney BC, Staatz CE.

Br J Clin Pharmacol. 2015 Nov;80(5):1064-75. doi: 10.1111/bcp.12678. Epub 2015 Jul 2.

16.

Osteoporosis medication dispensing for older Australian women from 2002 to 2010: influences of publications, guidelines, marketing activities and policy.

Peeters G, Tett SE, Duncan EL, Mishra GD, Dobson AJ.

Pharmacoepidemiol Drug Saf. 2014 Dec;23(12):1303-11. doi: 10.1002/pds.3703. Epub 2014 Aug 30.

PMID:
25174626
17.

Is statin use associated with new joint-related symptoms, physical function, and quality of life? Results from two population-based cohorts of women.

Peeters G, Tett SE, Conaghan PG, Mishra GD, Dobson AJ.

Arthritis Care Res (Hoboken). 2015 Jan;67(1):13-20. doi: 10.1002/acr.22389.

18.

Pharmacology and toxicology of mycophenolate in organ transplant recipients: an update.

Staatz CE, Tett SE.

Arch Toxicol. 2014 Jul;88(7):1351-89. doi: 10.1007/s00204-014-1247-1. Epub 2014 May 4. Review.

PMID:
24792322
19.

How accurate and precise are limited sampling strategies in estimating exposure to mycophenolic acid in people with autoimmune disease?

Abd Rahman AN, Tett SE, Staatz CE.

Clin Pharmacokinet. 2014 Mar;53(3):227-245. doi: 10.1007/s40262-013-0124-z. Review.

PMID:
24327238
20.

Safety evaluation of leflunomide in rheumatoid arthritis.

Keen HI, Conaghan PG, Tett SE.

Expert Opin Drug Saf. 2013 Jul;12(4):581-8. doi: 10.1517/14740338.2013.798299. Epub 2013 May 14. Review.

PMID:
23668332
21.

Differences in utilisation of gastroprotective drugs between 2001 and 2005 in Australia and Nova Scotia, Canada.

Tett SE, Sketris I, Cooke C, van Zanten SV, Barozzi N.

Pharmacoepidemiol Drug Saf. 2013 Jul;22(7):735-43. doi: 10.1002/pds.3442. Epub 2013 Apr 4.

PMID:
23559528
22.

Clinical pharmacokinetics and pharmacodynamics of mycophenolate in patients with autoimmune disease.

Abd Rahman AN, Tett SE, Staatz CE.

Clin Pharmacokinet. 2013 May;52(5):303-31. doi: 10.1007/s40262-013-0039-8. Review.

PMID:
23475567
23.

A cross-sectional study of hydroxychloroquine concentrations and effects in people with systemic lupus erythematosus.

Carmichael SJ, Day RO, Tett SE.

Intern Med J. 2013 May;43(5):547-53. doi: 10.1111/imj.12100.

PMID:
23425382
24.

Quality Use of Medicines--medication safety issues in naming; look-alike, sound-alike medicine names.

Ostini R, Roughead EE, Kirkpatrick CM, Monteith GR, Tett SE.

Int J Pharm Pract. 2012 Dec;20(6):349-57. doi: 10.1111/j.2042-7174.2012.00210.x. Epub 2012 May 18. Review.

PMID:
23134093
25.

Innovation in hospital quality improvement activities--acute postoperative pain management (APOP) self-help toolkit audits as an example.

Pulver LK, Oliver K, Tett SE.

J Healthc Qual. 2012 Jul-Aug;34(4):45-59. doi: 10.1111/j.1945-1474.2012.00207.x.

PMID:
22812687
26.

Validity of self-reported osteoporosis in mid-age and older women.

Peeters GM, Tett SE, Dobson AJ, Mishra GD.

Osteoporos Int. 2013 Mar;24(3):917-27. doi: 10.1007/s00198-012-2033-7. Epub 2012 Jun 7.

PMID:
22673826
27.

Consumers' experiences and values in conventional and alternative medicine paradigms: a problem detection study (PDS).

Emmerton L, Fejzic J, Tett SE.

BMC Complement Altern Med. 2012 Apr 10;12:39. doi: 10.1186/1472-6882-12-39.

28.

Knowing how to stop: ceasing prescribing when the medicine is no longer required.

Ostini R, Hegney D, Jackson C, Tett SE.

J Manag Care Pharm. 2012 Jan-Feb;18(1):68-72. No abstract available.

29.

Maximum a posteriori Bayesian estimation of mycophenolic Acid area under the concentration-time curve: is this clinically useful for dosage prediction yet?

Staatz CE, Tett SE.

Clin Pharmacokinet. 2011 Dec 1;50(12):759-72. doi: 10.2165/11596380-000000000-00000. Review.

PMID:
22087863
30.

Management of acute coronary syndromes at hospital discharge: do targeted educational interventions improve practice quality?

Peterson GM, Thompson A, Pulver LK, Robertson MB, Brieger D, Wai A, Tett SE; DMACS Project Group.

J Healthc Qual. 2012 Jan-Feb;34(1):26-34. doi: 10.1111/j.1945-1474.2011.00137.x. Epub 2011 Mar 1.

PMID:
22059443
31.

Population pharmacokinetics of fluconazole in critically ill patients receiving continuous venovenous hemodiafiltration: using Monte Carlo simulations to predict doses for specified pharmacodynamic targets.

Patel K, Roberts JA, Lipman J, Tett SE, Deldot ME, Kirkpatrick CM.

Antimicrob Agents Chemother. 2011 Dec;55(12):5868-73. doi: 10.1128/AAC.00424-11. Epub 2011 Sep 19.

32.

Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure.

Tett SE, Saint-Marcoux F, Staatz CE, Brunet M, Vinks AA, Miura M, Marquet P, Kuypers DR, van Gelder T, Cattaneo D.

Transplant Rev (Orlando). 2011 Apr;25(2):47-57. doi: 10.1016/j.trre.2010.06.001. Epub 2010 Dec 28.

PMID:
21190834
33.

A quality improvement initiative to improve adherence to national guidelines for empiric management of community-acquired pneumonia in emergency departments.

McIntosh KA, Maxwell DJ, Pulver LK, Horn F, Robertson MB, Kaye KI, Peterson GM, Dollman WB, Wai A, Tett SE.

Int J Qual Health Care. 2011 Apr;23(2):142-50. doi: 10.1093/intqhc/mzq077. Epub 2010 Dec 3.

PMID:
21131383
34.

Improving the use of benzodiazepines--is it possible? A non-systematic review of interventions tried in the last 20 years.

Smith AJ, Tett SE.

BMC Health Serv Res. 2010 Nov 30;10:321. doi: 10.1186/1472-6963-10-321. Review.

35.

How is medication prescribing ceased? A systematic review.

Ostini R, Jackson C, Hegney D, Tett SE.

Med Care. 2011 Jan;49(1):24-36. doi: 10.1097/MLR.0b013e3181ef9a7e. Review.

PMID:
20966784
36.

Towards concordance in healthcare: perspectives of general practitioners, complementary and alternative medicine practitioners and pharmacists in Australia.

Fejzic J, Emmerton L, Tett SE.

J Clin Pharm Ther. 2010 Jun;35(3):309-21. doi: 10.1111/j.1365-2710.2009.01093.x.

PMID:
20831532
37.

Community pharmacy dispensing of prescription medicine sample packs: changing the business of medicine initiation?

Kyle GJ, Nissen L, Tett S.

J Eval Clin Pract. 2010 Dec;16(6):1357-60. doi: 10.1111/j.1365-2753.2009.01290.x. No abstract available.

PMID:
20695957
38.

The contribution of injecting drug users in Sydney, Melbourne and Brisbane to rising benzodiazepine use in Australia 2000 to 2006.

Smith A, Tett S, Hall W.

Aust N Z J Public Health. 2010 Jun;34(3):315-9. doi: 10.1111/j.1753-6405.2010.00533.x.

PMID:
20618276
39.

An intervention to improve benzodiazepine use--a new approach.

Smith AJ, Tett SE.

Fam Pract. 2010 Jun;27(3):320-7. doi: 10.1093/fampra/cmq007. Epub 2010 Mar 17.

PMID:
20237108
40.

Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II.

Staatz CE, Goodman LK, Tett SE.

Clin Pharmacokinet. 2010 Apr;49(4):207-21. doi: 10.2165/11317550-000000000-00000. Review.

PMID:
20214406
41.

Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I.

Staatz CE, Goodman LK, Tett SE.

Clin Pharmacokinet. 2010 Mar;49(3):141-75. doi: 10.2165/11317350-000000000-00000. Review.

PMID:
20170205
42.

Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation.

Kuypers DR, Le Meur Y, Cantarovich M, Tredger MJ, Tett SE, Cattaneo D, Tönshoff B, Holt DW, Chapman J, Gelder Tv; Transplantation Society (TTS) Consensus Group on TDM of MPA.

Clin J Am Soc Nephrol. 2010 Feb;5(2):341-58. doi: 10.2215/CJN.07111009. Epub 2010 Jan 7. Review.

43.

Comparison of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 (COX-2) inhibitors use in Australia and Nova Scotia (Canada).

Barozzi N, Sketris I, Cooke C, Tett S.

Br J Clin Pharmacol. 2009 Jul;68(1):106-15. doi: 10.1111/j.1365-2125.2009.03410.x.

45.

Gastroprotective drugs in Australia: utilization patterns between 1997 and 2006 in relation to NSAID prescribing.

Barozzi N, Tett SE.

Clin Ther. 2009 Apr;31(4):849-61. doi: 10.1016/j.clinthera.2009.04.012.

PMID:
19446158
46.

Systematic review of interventions to improve prescribing.

Ostini R, Hegney D, Jackson C, Williamson M, Mackson JM, Gurman K, Hall W, Tett SE.

Ann Pharmacother. 2009 Mar;43(3):502-13. doi: 10.1345/aph.1L488. Epub 2009 Mar 3. Review.

PMID:
19261953
47.

A comparison of mycophenolate use in Australia and Northern Europe, and the impact on the pharmaceutical benefits scheme.

Staatz CE, Smith AJ, Tett SE.

Pharmacoepidemiol Drug Saf. 2009 May;18(5):386-92. doi: 10.1002/pds.1726.

PMID:
19253908
48.

How do different age groups use benzodiazepines and antidepressants? Analysis of an Australian administrative database, 2003-6.

Smith AJ, Tett SE.

Drugs Aging. 2009;26(2):113-22. doi: 10.2165/0002512-200926020-00003.

PMID:
19220068
49.
50.

Perceived barriers to paracetamol (acetaminophen) prescribing, especially following rofecoxib withdrawal from the market.

Barozzi N, Tett SE.

Clin Rheumatol. 2009 May;28(5):509-19. doi: 10.1007/s10067-008-1077-8. Epub 2009 Jan 9.

PMID:
19132456

Supplemental Content

Support Center